The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis
Recently, many reports showed that the pretransplant neutrophil-lymphocyte ratio (NLR) may be correlated with the prognosis of patients undergoing liver transplantation (LT) for hepatocellular cancer (HCC). However, their results still remained controversial. Thus we performed a meta-analysis of 13...
Gespeichert in:
| Veröffentlicht in: | Biomarkers in medicine 2018-02, Vol.12 (2), p.189-199 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 199 |
|---|---|
| container_issue | 2 |
| container_start_page | 189 |
| container_title | Biomarkers in medicine |
| container_volume | 12 |
| creator | Xu, Zheng-Guang Ye, Cheng-Jie Liu, Lin-Xun Wu, Gang Zhao, Zhan-Xue Wang, Yong-Zhen Shi, Bing-Qiang Wang, Yong-Hong |
| description | Recently, many reports showed that the pretransplant neutrophil-lymphocyte ratio (NLR) may be correlated with the prognosis of patients undergoing liver transplantation (LT) for hepatocellular cancer (HCC). However, their results still remained controversial. Thus we performed a meta-analysis of 13 studies to estimate the prognostic value of pretransplant NLR.
Databases including PubMed, Embase, Cochrane Library and Web of Science were searched to September 2017. Hazard ratio (HR) or odds ratio (OR) with its 95% CI was used to evaluate the association between elevated NLR and the prognosis or clinical features of liver cancer patients.
A total of 13 studies including 1936 patients were included in this meta-analysis. Elevated pretransplant NLR had a close association with the overall survival (HR: 2.22; 95% CI: 1.34-3.68), recurrence-free survival (HR: 3.77; 95% CI: 2.01-7.06) and disease-free survival (HR: 2.51; 95% CI: 1.22-5.15) of patients undergoing LT for HCC, respectively. In addition, elevated NLR was associated with the presence of vascular invasion (OR: 2.39; 95% CI: 1.20-4.77) and Milan criteria (OR: 0.26; 95% CI: 0.17-0.40).
The results of this meta-analysis showed that elevated pretransplant NLR may be used as a new prognostic predictor after LT for HCC. |
| doi_str_mv | 10.2217/bmm-2017-0307 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1989605646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216512141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-b7c5fe7626aa0d9a720cbd5d1e4e45aa8063090ad8582f4805cca3a50ceeb9073</originalsourceid><addsrcrecordid>eNp1kctq3jAQRk1paNK0y26LoJtu3EiyZdndldAbBLJJ12Isj_sr6OJKcoLfqI8ZmT9NodCNLujMYUZfVb1h9APnTF6MztWcMlnThspn1RmTgpezZM-fzl1zWr1M6ZZSIWXHX1SnfGi4FIM4q37fHJAsEXMEnxYLPhOPa45hORhb280th6C3jCRCNoFAIlCA-1ISfvqQstF79WR0DpHAnDESa-7K-le4F3oyl_cDLpCDRmtXC5Fo8Brjx2JMW8roYLdFvDPFD34iDjPU4MFuyaRX1ckMNuHrx_28-vHl883lt_rq-uv3y09XtS4z53qUWsxYpuwA6DSA5FSPk5gYttgKgJ52DR0oTL3o-dz2VGgNDQiqEceByua8en_0lgl_rZiycibtLYPHsCbFhn7oqOjarqDv_kFvwxpLv0mVaDrBOGtZoeojpWNIKeKslmgcxE0xunNSlQjVHqHaIyz820frOjqcnug_mRVgOALzmteISRss_6iON7dnYTz-R_4ASZGv0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216512141</pqid></control><display><type>article</type><title>The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Xu, Zheng-Guang ; Ye, Cheng-Jie ; Liu, Lin-Xun ; Wu, Gang ; Zhao, Zhan-Xue ; Wang, Yong-Zhen ; Shi, Bing-Qiang ; Wang, Yong-Hong</creator><creatorcontrib>Xu, Zheng-Guang ; Ye, Cheng-Jie ; Liu, Lin-Xun ; Wu, Gang ; Zhao, Zhan-Xue ; Wang, Yong-Zhen ; Shi, Bing-Qiang ; Wang, Yong-Hong</creatorcontrib><description>Recently, many reports showed that the pretransplant neutrophil-lymphocyte ratio (NLR) may be correlated with the prognosis of patients undergoing liver transplantation (LT) for hepatocellular cancer (HCC). However, their results still remained controversial. Thus we performed a meta-analysis of 13 studies to estimate the prognostic value of pretransplant NLR.
Databases including PubMed, Embase, Cochrane Library and Web of Science were searched to September 2017. Hazard ratio (HR) or odds ratio (OR) with its 95% CI was used to evaluate the association between elevated NLR and the prognosis or clinical features of liver cancer patients.
A total of 13 studies including 1936 patients were included in this meta-analysis. Elevated pretransplant NLR had a close association with the overall survival (HR: 2.22; 95% CI: 1.34-3.68), recurrence-free survival (HR: 3.77; 95% CI: 2.01-7.06) and disease-free survival (HR: 2.51; 95% CI: 1.22-5.15) of patients undergoing LT for HCC, respectively. In addition, elevated NLR was associated with the presence of vascular invasion (OR: 2.39; 95% CI: 1.20-4.77) and Milan criteria (OR: 0.26; 95% CI: 0.17-0.40).
The results of this meta-analysis showed that elevated pretransplant NLR may be used as a new prognostic predictor after LT for HCC.</description><identifier>ISSN: 1752-0363</identifier><identifier>EISSN: 1752-0371</identifier><identifier>DOI: 10.2217/bmm-2017-0307</identifier><identifier>PMID: 29327595</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Blood platelets ; Carcinoma, Hepatocellular - diagnosis ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - therapy ; Chemotherapy ; Disease-Free Survival ; hepatocellular cancer ; Humans ; Inflammation ; Liver cancer ; Liver Neoplasms - diagnosis ; Liver Neoplasms - mortality ; Liver Neoplasms - therapy ; Liver Transplantation ; Liver transplants ; Lymphocytes ; Lymphocytes - cytology ; Medical prognosis ; Meta-analysis ; neutrophil-lymphocyte ratio ; Neutrophils ; Neutrophils - cytology ; Odds Ratio ; Prognosis ; Proportional Hazards Models ; Studies ; Systematic review ; Transplants & implants ; Tumors</subject><ispartof>Biomarkers in medicine, 2018-02, Vol.12 (2), p.189-199</ispartof><rights>2018 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Feb 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-b7c5fe7626aa0d9a720cbd5d1e4e45aa8063090ad8582f4805cca3a50ceeb9073</citedby><cites>FETCH-LOGICAL-c371t-b7c5fe7626aa0d9a720cbd5d1e4e45aa8063090ad8582f4805cca3a50ceeb9073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29327595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Zheng-Guang</creatorcontrib><creatorcontrib>Ye, Cheng-Jie</creatorcontrib><creatorcontrib>Liu, Lin-Xun</creatorcontrib><creatorcontrib>Wu, Gang</creatorcontrib><creatorcontrib>Zhao, Zhan-Xue</creatorcontrib><creatorcontrib>Wang, Yong-Zhen</creatorcontrib><creatorcontrib>Shi, Bing-Qiang</creatorcontrib><creatorcontrib>Wang, Yong-Hong</creatorcontrib><title>The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis</title><title>Biomarkers in medicine</title><addtitle>Biomark Med</addtitle><description>Recently, many reports showed that the pretransplant neutrophil-lymphocyte ratio (NLR) may be correlated with the prognosis of patients undergoing liver transplantation (LT) for hepatocellular cancer (HCC). However, their results still remained controversial. Thus we performed a meta-analysis of 13 studies to estimate the prognostic value of pretransplant NLR.
Databases including PubMed, Embase, Cochrane Library and Web of Science were searched to September 2017. Hazard ratio (HR) or odds ratio (OR) with its 95% CI was used to evaluate the association between elevated NLR and the prognosis or clinical features of liver cancer patients.
A total of 13 studies including 1936 patients were included in this meta-analysis. Elevated pretransplant NLR had a close association with the overall survival (HR: 2.22; 95% CI: 1.34-3.68), recurrence-free survival (HR: 3.77; 95% CI: 2.01-7.06) and disease-free survival (HR: 2.51; 95% CI: 1.22-5.15) of patients undergoing LT for HCC, respectively. In addition, elevated NLR was associated with the presence of vascular invasion (OR: 2.39; 95% CI: 1.20-4.77) and Milan criteria (OR: 0.26; 95% CI: 0.17-0.40).
The results of this meta-analysis showed that elevated pretransplant NLR may be used as a new prognostic predictor after LT for HCC.</description><subject>Blood platelets</subject><subject>Carcinoma, Hepatocellular - diagnosis</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Chemotherapy</subject><subject>Disease-Free Survival</subject><subject>hepatocellular cancer</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver Transplantation</subject><subject>Liver transplants</subject><subject>Lymphocytes</subject><subject>Lymphocytes - cytology</subject><subject>Medical prognosis</subject><subject>Meta-analysis</subject><subject>neutrophil-lymphocyte ratio</subject><subject>Neutrophils</subject><subject>Neutrophils - cytology</subject><subject>Odds Ratio</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Studies</subject><subject>Systematic review</subject><subject>Transplants & implants</subject><subject>Tumors</subject><issn>1752-0363</issn><issn>1752-0371</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kctq3jAQRk1paNK0y26LoJtu3EiyZdndldAbBLJJ12Isj_sr6OJKcoLfqI8ZmT9NodCNLujMYUZfVb1h9APnTF6MztWcMlnThspn1RmTgpezZM-fzl1zWr1M6ZZSIWXHX1SnfGi4FIM4q37fHJAsEXMEnxYLPhOPa45hORhb280th6C3jCRCNoFAIlCA-1ISfvqQstF79WR0DpHAnDESa-7K-le4F3oyl_cDLpCDRmtXC5Fo8Brjx2JMW8roYLdFvDPFD34iDjPU4MFuyaRX1ckMNuHrx_28-vHl883lt_rq-uv3y09XtS4z53qUWsxYpuwA6DSA5FSPk5gYttgKgJ52DR0oTL3o-dz2VGgNDQiqEceByua8en_0lgl_rZiycibtLYPHsCbFhn7oqOjarqDv_kFvwxpLv0mVaDrBOGtZoeojpWNIKeKslmgcxE0xunNSlQjVHqHaIyz820frOjqcnug_mRVgOALzmteISRss_6iON7dnYTz-R_4ASZGv0Q</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Xu, Zheng-Guang</creator><creator>Ye, Cheng-Jie</creator><creator>Liu, Lin-Xun</creator><creator>Wu, Gang</creator><creator>Zhao, Zhan-Xue</creator><creator>Wang, Yong-Zhen</creator><creator>Shi, Bing-Qiang</creator><creator>Wang, Yong-Hong</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis</title><author>Xu, Zheng-Guang ; Ye, Cheng-Jie ; Liu, Lin-Xun ; Wu, Gang ; Zhao, Zhan-Xue ; Wang, Yong-Zhen ; Shi, Bing-Qiang ; Wang, Yong-Hong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-b7c5fe7626aa0d9a720cbd5d1e4e45aa8063090ad8582f4805cca3a50ceeb9073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood platelets</topic><topic>Carcinoma, Hepatocellular - diagnosis</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Chemotherapy</topic><topic>Disease-Free Survival</topic><topic>hepatocellular cancer</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver Transplantation</topic><topic>Liver transplants</topic><topic>Lymphocytes</topic><topic>Lymphocytes - cytology</topic><topic>Medical prognosis</topic><topic>Meta-analysis</topic><topic>neutrophil-lymphocyte ratio</topic><topic>Neutrophils</topic><topic>Neutrophils - cytology</topic><topic>Odds Ratio</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Studies</topic><topic>Systematic review</topic><topic>Transplants & implants</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Zheng-Guang</creatorcontrib><creatorcontrib>Ye, Cheng-Jie</creatorcontrib><creatorcontrib>Liu, Lin-Xun</creatorcontrib><creatorcontrib>Wu, Gang</creatorcontrib><creatorcontrib>Zhao, Zhan-Xue</creatorcontrib><creatorcontrib>Wang, Yong-Zhen</creatorcontrib><creatorcontrib>Shi, Bing-Qiang</creatorcontrib><creatorcontrib>Wang, Yong-Hong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Biomarkers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Zheng-Guang</au><au>Ye, Cheng-Jie</au><au>Liu, Lin-Xun</au><au>Wu, Gang</au><au>Zhao, Zhan-Xue</au><au>Wang, Yong-Zhen</au><au>Shi, Bing-Qiang</au><au>Wang, Yong-Hong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis</atitle><jtitle>Biomarkers in medicine</jtitle><addtitle>Biomark Med</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>12</volume><issue>2</issue><spage>189</spage><epage>199</epage><pages>189-199</pages><issn>1752-0363</issn><eissn>1752-0371</eissn><abstract>Recently, many reports showed that the pretransplant neutrophil-lymphocyte ratio (NLR) may be correlated with the prognosis of patients undergoing liver transplantation (LT) for hepatocellular cancer (HCC). However, their results still remained controversial. Thus we performed a meta-analysis of 13 studies to estimate the prognostic value of pretransplant NLR.
Databases including PubMed, Embase, Cochrane Library and Web of Science were searched to September 2017. Hazard ratio (HR) or odds ratio (OR) with its 95% CI was used to evaluate the association between elevated NLR and the prognosis or clinical features of liver cancer patients.
A total of 13 studies including 1936 patients were included in this meta-analysis. Elevated pretransplant NLR had a close association with the overall survival (HR: 2.22; 95% CI: 1.34-3.68), recurrence-free survival (HR: 3.77; 95% CI: 2.01-7.06) and disease-free survival (HR: 2.51; 95% CI: 1.22-5.15) of patients undergoing LT for HCC, respectively. In addition, elevated NLR was associated with the presence of vascular invasion (OR: 2.39; 95% CI: 1.20-4.77) and Milan criteria (OR: 0.26; 95% CI: 0.17-0.40).
The results of this meta-analysis showed that elevated pretransplant NLR may be used as a new prognostic predictor after LT for HCC.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29327595</pmid><doi>10.2217/bmm-2017-0307</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1752-0363 |
| ispartof | Biomarkers in medicine, 2018-02, Vol.12 (2), p.189-199 |
| issn | 1752-0363 1752-0371 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1989605646 |
| source | MEDLINE; PubMed Central |
| subjects | Blood platelets Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - therapy Chemotherapy Disease-Free Survival hepatocellular cancer Humans Inflammation Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - mortality Liver Neoplasms - therapy Liver Transplantation Liver transplants Lymphocytes Lymphocytes - cytology Medical prognosis Meta-analysis neutrophil-lymphocyte ratio Neutrophils Neutrophils - cytology Odds Ratio Prognosis Proportional Hazards Models Studies Systematic review Transplants & implants Tumors |
| title | The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T16%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20pretransplant%20neutrophil-lymphocyte%20ratio%20as%20a%20new%20prognostic%20predictor%20after%20liver%20transplantation%20for%20hepatocellular%20cancer:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Biomarkers%20in%20medicine&rft.au=Xu,%20Zheng-Guang&rft.date=2018-02-01&rft.volume=12&rft.issue=2&rft.spage=189&rft.epage=199&rft.pages=189-199&rft.issn=1752-0363&rft.eissn=1752-0371&rft_id=info:doi/10.2217/bmm-2017-0307&rft_dat=%3Cproquest_cross%3E2216512141%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216512141&rft_id=info:pmid/29327595&rfr_iscdi=true |